BrainAurora Medical Technology Limited (6681) introduced a Nomination Committee framework pursuant to a board resolution passed on November 18, 2025. The committee was formally established on December 19, 2024, with its purpose defined as identifying and recommending qualified candidates for directorships, overseeing the Board’s performance evaluation process, and advocating guidelines consistent with relevant regulations.
The Terms of Reference specify that committee members must include at least three directors, with a majority being independent non-executive directors and at least one member of a different gender. Meetings are to be held at least once annually, and senior management is required to provide complete and reliable information for the committee’s review.
Among the primary duties are assessing the Board’s structure, size, and skill set; recommending appointments or re-appointments of directors; verifying the independence of independent non-executive directors; and evaluating the company’s leadership needs on an ongoing basis. The committee is empowered to seek independent professional advice at the company’s expense and to maintain careful documentation of all proceedings for regular reporting to the Board.
Other responsibilities include making succession plans, suggesting membership changes in key committees, and overseeing any agreements related to compensation or involvement of directors in research and development efforts. The Terms of Reference are available in both English and Chinese, with the English version prevailing in case of discrepancies.
Comments